当前位置: X-MOL 学术J. Mol. Struct. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Evaluation of the binding behavior of olmutinib (HM61713) with model transport protein: Insights from spectroscopic and molecular docking studies
Journal of Molecular Structure ( IF 3.8 ) Pub Date : 2021-01-01 , DOI: 10.1016/j.molstruc.2020.129024
Song-Bo Kou , Zhen-Yi Lin , Bao-Li Wang , Jie-Hua Shi , Ying-Xin Liu

Abstract Olmutinib (HM61713, OMT), a novel third-generation tyrosine kinase inhibitor with good orally absorption, is able to inhibit selectively epidermal growth factor receptor mutations. In this work, the binding behavior of OMT with model transport protein bovine serum albumin (BSA) was assessed with the help of spectroscopic and molecular docking approaches. A fluorescence quenching of BSA was observed during the binding interaction of OMT with BSA, followed by a static mechanism was demonstrated. The affinity of OMT with BSA was moderate due to the binding constant of 2.75 × 105 M−1 at 293 K. The hydrophobic interactions, hydrogen bonds as well as van der Waals forces were acting as the predominant contributions in the OMT-BSA complexation process. The findings from site competitive experiments revealed that OMT tended to bind to subdomain IB (site III) of BSA, which was in keep with the outcomes of molecular docking studies. Based on synchronous and 3D fluorescence studies, we found that the conformation of BSA was changed owing to the binding with OMT. The FT-IR and UV-Vis studies further corroborated that the binding of OMT to BSA changed the secondary structure of BSA. Additionally, the experimental data showed that some metal ions (e.g. Ni2+, Fe3+, Mg2+, Cu2+) could promote the binding interaction of OMT with BSA. This study is beneficial to further assess the pharmacological properties of OMT and can provide valuable reference for designing new anti-tumor drugs.

中文翻译:

奥穆替尼 (HM61713) 与模型转运蛋白结合行为的评估:光谱和分子对接研究的见解

摘要 Olmutinib (HM61713, OMT) 是一种新型的第三代酪氨酸激酶抑制剂,口服吸收良好,能够选择性抑制表皮生长因子受体突变。在这项工作中,借助光谱和分子对接方法评估了 OMT 与模型转运蛋白牛血清白蛋白 (BSA) 的结合行为。在 OMT 与 BSA 的结合相互作用期间观察到 BSA 的荧光猝灭,随后证明了静态机制。由于在 293 K 时的结合常数为 2.75 × 105 M-1,OMT 与 BSA 的亲和力适中。疏水相互作用、氢键以及范德华力在 OMT-BSA 复合过程中起主要作用. 位点竞争实验的结果表明,OMT 倾向于与 BSA 的子域 IB(位点 III)结合,这与分子对接研究的结果一致。基于同步和 3D 荧光研究,我们发现 BSA 的构象由于与 OMT 的结合而发生变化。FT-IR 和 UV-Vis 研究进一步证实了 OMT 与 BSA 的结合改变了 BSA 的二级结构。此外,实验数据表明,一些金属离子(如 Ni2+、Fe3+、Mg2+、Cu2+)可以促进 OMT 与 BSA 的结合相互作用。本研究有利于进一步评估OMT的药理特性,为设计新的抗肿瘤药物提供有价值的参考。基于同步和 3D 荧光研究,我们发现 BSA 的构象由于与 OMT 的结合而发生变化。FT-IR 和 UV-Vis 研究进一步证实了 OMT 与 BSA 的结合改变了 BSA 的二级结构。此外,实验数据表明,一些金属离子(如 Ni2+、Fe3+、Mg2+、Cu2+)可以促进 OMT 与 BSA 的结合相互作用。本研究有利于进一步评估OMT的药理特性,为设计新的抗肿瘤药物提供有价值的参考。基于同步和 3D 荧光研究,我们发现 BSA 的构象由于与 OMT 的结合而发生变化。FT-IR 和 UV-Vis 研究进一步证实了 OMT 与 BSA 的结合改变了 BSA 的二级结构。此外,实验数据表明,一些金属离子(如 Ni2+、Fe3+、Mg2+、Cu2+)可以促进 OMT 与 BSA 的结合相互作用。本研究有利于进一步评估OMT的药理特性,为设计新的抗肿瘤药物提供有价值的参考。Cu2+) 可以促进 OMT 与 BSA 的结合相互作用。本研究有利于进一步评估OMT的药理特性,为设计新的抗肿瘤药物提供有价值的参考。Cu2+) 可以促进 OMT 与 BSA 的结合相互作用。本研究有利于进一步评估OMT的药理特性,为设计新的抗肿瘤药物提供有价值的参考。
更新日期:2021-01-01
down
wechat
bug